Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard M J Uitdehaag

Showing results (1-10 of 223) with videos related to

Pageof 23
Sort By:
CNS Drugs|June 22, 2018
Disability Outcome Measures in Phase III Clinical Trials in Multiple SclerosisBernard M J Uitdehaag
Handbook of Clinical Neurology|February 11, 2014
Clinical outcome measures in multiple sclerosisBernard M J Uitdehaag
The Lancet. Neurology|August 28, 2003
New and emerging treatment options for multiple sclerosisChris H Polman, Bernard M J Uitdehaag
CNS Drugs|February 11, 2017
Outcome Measures in Clinical Trials for Multiple SclerosisCaspar E P van Munster, Bernard M J Uitdehaag
JAMA|August 14, 2003
Cannabinoids and immune functionJoep Killestein, Bernard M J Uitdehaag, Chris H Polman
European Neurology|March 21, 2017
Regression-Based Norms for the Symbol Digit Modalities Test in the Dutch Population: Improving Detection of Cognitive Impairment in Multiple Sclerosis?Jessica Burggraaff, Dirk L Knol, Bernard M J Uitdehaag
Drugs|January 16, 2004
Cannabinoids in multiple sclerosis: do they have a therapeutic role?Joep Killestein, Bernard M J Uitdehaag, Chris H Polman
Annals of Neurology|April 11, 2022
Interpretation of Longitudinal Changes of the Inner Nuclear Layer in MSJenny A Nij Bijvank, Bernard M J Uitdehaag, Axel Petzold
Journal of Neurology|October 9, 2013
Physiological variation of segmented OCT retinal layer thicknesses is short-lastingLisanne Balk, Markus Mayer, Bernard M J Uitdehaag, et al.
Journal of the Neurological Sciences|March 25, 2018
Software updates of OCT segmentation algorithms influence longitudinal assessment of retinal atrophyDanko Coric, Axel Petzold, Bernard M J Uitdehaag, et al.
Pageof 23

Showing results (1-10 of 223) with videos related to

Sort By:
Pageof 23
CNS Drugs|June 22, 2018
Disability Outcome Measures in Phase III Clinical Trials in Multiple SclerosisBernard M J Uitdehaag
Handbook of Clinical Neurology|February 11, 2014
Clinical outcome measures in multiple sclerosisBernard M J Uitdehaag
The Lancet. Neurology|August 28, 2003
New and emerging treatment options for multiple sclerosisChris H Polman, Bernard M J Uitdehaag
CNS Drugs|February 11, 2017
Outcome Measures in Clinical Trials for Multiple SclerosisCaspar E P van Munster, Bernard M J Uitdehaag
JAMA|August 14, 2003
Cannabinoids and immune functionJoep Killestein, Bernard M J Uitdehaag, Chris H Polman
European Neurology|March 21, 2017
Regression-Based Norms for the Symbol Digit Modalities Test in the Dutch Population: Improving Detection of Cognitive Impairment in Multiple Sclerosis?Jessica Burggraaff, Dirk L Knol, Bernard M J Uitdehaag
Drugs|January 16, 2004
Cannabinoids in multiple sclerosis: do they have a therapeutic role?Joep Killestein, Bernard M J Uitdehaag, Chris H Polman
Annals of Neurology|April 11, 2022
Interpretation of Longitudinal Changes of the Inner Nuclear Layer in MSJenny A Nij Bijvank, Bernard M J Uitdehaag, Axel Petzold
Journal of Neurology|October 9, 2013
Physiological variation of segmented OCT retinal layer thicknesses is short-lastingLisanne Balk, Markus Mayer, Bernard M J Uitdehaag, et al.
Journal of the Neurological Sciences|March 25, 2018
Software updates of OCT segmentation algorithms influence longitudinal assessment of retinal atrophyDanko Coric, Axel Petzold, Bernard M J Uitdehaag, et al.
Pageof 23